Aliri USA
Aliri USA is recorded as a service provider in 15 clinical trials. Explore its recorded services, study phases and therapeutic areas, with trial-level operational learnings where available.
Clinical trial experience
Showing 15 of 15 trials · Latest update first
TRITON-PN: A Phase 3, Global, Randomized, Open-Label Study to Evaluate the Efficacy and Safety of Nucresiran in Patients with Hereditary Transthyretin-Mediated Amyloidosis with Polyneuropathy (hATTR-PN)
Sponsor Alnylam Pharmaceuticals Inc.
- Start (EU)
- Latest update
- Estimated end
A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Proof of Concept (POC) Study Evaluating the Safety, Tolerability, and Efficacy of Nintedanib Solution for Inhalation (AP02) in Participants with Idiopathic Pulmonary Fibrosis (IPF) (AURA-IPF)
Sponsor Avalyn Pharma Inc.
- Start (EU)
- Latest update
- Estimated end
Proof of concept study to assess the efficacy and safety of Danicopan (factor D inhibitor) in adult patients with chronic spontaneous urticaria resistant to H1-antihistamine treatment (DANICSU).
Sponsor Fraunhofer Institute For Translational Medicine And Pharmacology ITMP
- Start (EU)
- Not reported
- Latest update
- Estimated end
- Not reported
Operational learnings available2 trial-level findings · Read insights
- No study centers were initiated before the end-of-trial notification on 20 October 2024.
- No patients were enrolled before the end-of-trial notification on 20 October 2024.
These findings describe the trial, not the service provider’s performance or responsibility.
J3L-MC-EZEJ: A Phase 3, Randomized, Double-Blind, Placebo-Controlled Trial of Lepodisiran to Investigate the Effect on Coronary Plaque in Adults With Elevated Lp(a) Who Have Established Atherosclerotic Cardiovascular Disease or Are at Risk for a First Cardiovascular Event
Sponsor Eli Lilly & Co.
- Start (EU)
- Latest update
- Estimated end
TSRA196-AAT-201: A Phase 1/2, Open-Label, Multi-Center, Dose Escalation, Dose Expansion, and Single Repeat Dose Study of TSRA-196 in Adults With the PiZZ Genotype Who Have Lung and/or Liver Disease Associated with Severe Alpha-1 Antitrypsin Deficiency
Sponsor Tessera Therapeutics Inc.
- Start (EU)
- Not reported
- Latest update
- Estimated end
A Master Protocol for the Multi-cohort, Open-label, Phase 1/2 Study of DCC-3084 as Monotherapy and in Combination With Other Anticancer Agents in Participants With Advanced Malignancies Driven by the MAPK Pathway
Sponsor Deciphera Pharmaceuticals Inc.
- Start (EU)
- Not reported
- Latest update
- Estimated end
A Randomized, Placebo-Controlled, Double-Blind, Multicenter, Phase 3 Trial of Quemliclustat and Chemotherapy Versus Placebo and Chemotherapy in Patients With Treatment-Naive Metastatic Pancreatic Ductal Adenocarcinoma
Sponsor Arcus Biosciences Inc.
- Start (EU)
- Latest update
- Estimated end
A Phase 1b Trial of ARV-471 in Combination with Everolimus in Patients with ER+, HER2– Advanced or Metastatic Breast Cancer
Sponsor Arvinas Estrogen Receptor Inc.
- Start (EU)
- Latest update
- Estimated end
A Phase 1/2, Randomized, Double-blind, Placebo-controlled 2-part Study of the Safety, Tolerability, Efficacy, Pharmacokinetics, and Pharmacodynamics of Single Dose ALN-4324 in Overweight to Obese Adult Healthy Volunteers and Multiple Dose ALN-4324 in Overweight to Obese Patients With Type 2 Diabetes Mellitus (T2DM)
Sponsor Alnylam Pharmaceuticals Inc.
- Start (EU)
- Latest update
- Estimated end
A Phase 2, Randomized, Double-blinded, Placebo-controlled, Dose Range-finding, Multicenter Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of ALXN2420, a Growth Hormone Receptor Antagonist, Administered Subcutaneously in Combination with Somatostatin Analogs in Adult Participants with Acromegaly
Sponsor Alexion Pharmaceuticals Inc.
- Start (EU)
- Latest update
- Estimated end
A Phase II, Open-label, Platform Study, to Evaluate Immunotherapy-based Combinations in Participants With Advanced Non-Small Cell Lung Cancer
Sponsor Gilead Sciences Inc.
- Start (EU)
- Latest update
- Estimated end
A Phase 2, Randomized, Placebo-Controlled Trial to Assess the Efficacy and Safety of Mosliciguat in Participants with Pulmonary Hypertension Associated with Interstitial Lung Disease
Sponsor Pulmovant Inc.
- Start (EU)
- Latest update
- Estimated end
A Phase 2, Open-label, Multiple Ascending-Dose Study to Evaluate the Safety, Tolerability and Efficacy of ARCT-032 in People with Cystic Fibrosis
Sponsor Arcturus Therapeutics Europe B.V.
- Start (EU)
- Not reported
- Latest update
- Estimated end
A Phase 3, Randomized, Double-blind, Placebo-controlled Multicenter Study to Evaluate the Efficacy and Safety of Patisiran in Patients with Transthyretin Amyloidosis with Cardiomyopathy (ATTR Amyloidosis with Cardiomyopathy)
Sponsor Alnylam Pharmaceuticals Inc.
- Start (EU)
- Latest update
- Estimated end
A 52-Week Open-Label Extension Study of Pimavanserin in Children and Adolescents with Irritability Associated with Autism Spectrum Disorder (ASD)
Sponsor Acadia Pharmaceuticals Inc.
- Start (EU)
- Latest update
- Estimated end
Questions about this trial experience
What services are recorded for Aliri USA?
The 2026-10-09 snapshot links Aliri USA to 15 distinct CTIS trials. Recorded services include Laboratory services, PK Analysis, PK analysis sample management - PK (plasma), PK sample storage, processing and analysis. These are study-specific roles, not a complete or independently verified capability catalogue.
Which therapeutic areas and study phases are recorded for Aliri USA?
The most frequently recorded therapeutic areas are Genetic and Congenital Disorders, Respiratory, Allergy, Cardiology. Recorded phases include Phase 2, Phase 3, Phase 1. Use the filters to inspect the supporting studies; missing tags are not evidence of absent experience.
In which countries are trials linked to Aliri USA conducted?
The linked trials record locations in 19 countries, including Spain, Italy, Germany, France, Poland. These are trial locations, not confirmed office locations or countries where Aliri USA delivered services.
What can this page tell me about Aliri USA's trial experience?
Browse 15 distinct trials with recorded roles, sponsor names, available study dates and links to CTIS source records. 1 trials have operational findings that can inform further due diligence. Trial counts and findings do not measure the provider’s performance or establish responsibility for study outcomes.
About this data & company names
One current approved profile per CTIS trial. Services reflect recorded roles, not a complete capability catalogue or a performance ranking. Missing tags mean the information was not recorded. Country tags describe trial locations, not the provider’s service territory.
Start is the reported EU start date; latest update is the CTIS publication date; estimated end is the reported global estimate, which may be in the past. Missing dates are shown as “Not reported”. Operational learnings describe the trial as a whole and do not establish the provider’s responsibility.
Clear service synonyms are grouped; otherwise the source label is retained. Service tags show the recorded roles for each trial. This page groups 1 recorded name variant under Aliri USA. Legacy brands remain separate unless explicitly matched in the name registry.
View recorded company names
- Aliri USA Inc.